Reuters

01 Jun 2026, 09:37 UTC · 1h ago

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

Source · https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-partners-with-global-health-coalition-develop-bundibugyo-ebola-vaccine-2026-06-01/

Read source

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
Moderna has partnered with the Coalition for Epidemic Preparedness Innovations to develop a vaccine against Bundibugyo ebolavirus. — Expansion of mRNA vaccine pipeline into new indications creates long-term growth optionality, though the niche market size limits immediate price movement.
+0.20

Ticker attribution

Model heads

Sentiment in this article

MRNA+0.40
The company is expanding its vaccine pipeline through a new strategic partnership to combat ebolavirus.

Relationships in this article

No ticker relationship head found.

Impact vectors

1 dimensions · 9 clusters

6 related stories

Globe News Wire
1h ago
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
- biotech
- healthcare
Read

News Impact Screener — Catch market-moving news before the crowd

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

What matters in this story

Sentiment in this article

Relationships in this article

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

What matters in this story

Sentiment in this article

Relationships in this article

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

GRAIL's Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

What matters in this story

Sentiment in this article

Relationships in this article

Next reads from the same story arc

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

What matters in this story

Sentiment in this article

Relationships in this article

Next reads from the same story arc

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

GRAIL's Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint